Sign Up 
Early Diagnosis of Kidney Disease CKD Through Innovative Technological Solutions
Test
Challenge to the innovation ecosystem
EARLY DIAGNOSIS OF CHRONIC KIDNEY DISEASE (CKD) THROUGHINNOVATIVE TECHNOLOGICAL SOLUTIONS
Overview of the Condition
Chronic kidney disease (CKD) is defined by the presence of alterations in renal structure or function for a period of more than 3 months with health consequences, regardless of the cause. It is currently recognized as a major sociosanitary issue that requires a multidisciplinary and integrated approach. It is becoming increasingly relevant due to the morbidity and mortality associated with the patients affected. From a clinical point of view, early detection and diagnosis is essential, as it is a silent pathology, symptoms first start to manifest at advanced stages.
Challenge to the Innovation Ecosystem
At AstraZeneca, we are convinced that technology can improve the prevention of future diseases. The capability of digital technologies to improve early diagnosis is already a reality, and the healthcare sector is rapidly evolving thanks to such disruptive technologies. The wide range of technologies available represent a natural call to action to ensure Chronic Kidney Disease early diagnosis, slowing its progression and ensuring rapid intervene of population at highest risk of CKD, including patients with type 2 diabetes, hypertension, and cardiovascular disease.
This Open innovation call aims to support the development of projects that, through technology, will help reduce the burden of Chronic Kidney Disease thanks to an early diagnosis.
Do you want to respond to the challenge?
Join us in our mission to shape the future of health care
Want be our next partner? If you have the ambition to improve the quality of life of patients around the world, we want to hear from you. Send your proposal!
Summary of the Open Call
Jun 8th, 2022
Opening of the Call
Sept 8th, 2022
Application deadline
Sept 20th, 2022
Communication of shortlisted candidates
Oct 10th, 2022
Pitch to the Selection Committee
Oct 14th, 2022
Communication of finalists
Oct, 2022
Selection of the winner
Benefits
The winning project will be able to benefit from:
Funding and development of the pilot
Ad-hoc partnership with AstraZeneca Spain for the funding and development of the project pilot within the Spanish Healthcare System. €40,000 will be granted, primarily for the funding of the pilot. The partnership and the development of the pilot will be agreed on separate terms to this Call for Proposals.
The project will be shared with our global network of Innovation Hubs (A. Catalyst Network). A successful pilot could be piloted or escalated internationally. The A. Catalyst network will provide access to international Subject Matter Experts and partners (tech, academic, investors, etc.) from Innovation Hubs around the world.
Access and mentoring
Access to AstraZeneca Spain’s network of healthcare experts, opinion leaders and other health sector professionals who will guide the development of the project through mentoring sessions and advisory boards.
Access to AstraZeneca Spain’s experts in different technological areas, as well as technical support to the projects through our technology partners. 1-to-1 mentoring with professionals from AstraZeneca and its innovation ecosystem and partners. Access and connection to investors through our innovation ecosystem in Spain.
Business development
Business development opportunities through access to AstraZeneca Spain business units and professionals, by conducting meetings to discuss project opportunities and challenges.
Brand recognition
Brand recognition, dissemination and communication of the alliance and the project throughout the innovation ecosystem.
Partners
